Structural mechanism for signal transduction in RXR nuclear receptor heterodimers

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kojetin, Douglas J ^a   Matta Camacho, Edna ^a   Hughes, Travis S ^a   Srinivasan, Sathish ^a   Nwachukwu, Jerome C ^a   Cavett, Valerie ^a   Nowak, Jason ^a   Chalmers, Michael J ^a   Marciano, David P ^a   Kamenecka, Theodore M ^a   Shulman, Andrew I ^b,e   Rance, Mark ^c   Griffin, Patrick R ^a   Bruning, John B ^d   Nettles, Kendall W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR;

AMINO ACID; HORMONE; LIGAND; NUCLEAR MAGNETIC RESONANCE; PHYSIOLOGICAL RESPONSE; SIGNAL;

ALLOSTERISM; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; MOLECULAR DYNAMICS; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR CLONING; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; CELL LINE; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; GENE EXPRESSION REGULATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PPAR GAMMA; PROTEIN CONFORMATION; RECEPTORS, THYROID HORMONE; RETINOID X RECEPTOR ALPHA; SIGNAL TRANSDUCTION;

EID: 84939817933     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9013     Document Type: Article

References (70)

1. Shulman, A. I. & Mangelsdorf, D. J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353, 604-615 (2005).
2. Rosenfeld, M. G., Lunyak, V. V. & Glass, C. K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20, 1405-1428 (2006).
3. Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002).
4. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456 (2010).
5. Marciano, D. P. et al. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. Cell Metab. 19, 193-208 (2014).
6. Meijsing, S. H. et al. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324, 407-410 (2009).
7. Zhang, J. et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat. Struct. Mol. Biol. 18, 556-563 (2011).
8. Watson, L. C. et al. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Nat. Struct. Mol. Biol. 20, 876-883 (2013).
9. Zhang, J., Hu, X. & Lazar, M. A. A novel role for helix 12 of retinoid X receptor in regulating repression. Mol. Cell. Biol. 19, 6448-6457 (1999).
10. Shulman, A. I., Larson, C., Mangelsdorf, D. J. & Ranganathan, R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116, 417-429 (2004).
11. Nwachukwu, J. C. & Nettles, K. W. The nuclear receptor signalling scaffold: insights from full-length structures. EMBO J. 31, 251-253 (2012).
12. Rastinejad, F., Ollendorff, V. & Polikarpov, I. Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. Trends Biochem. Sci. 40, 16-24 (2015).
13. Nettles, K. W. & Greene, G. L. Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 67, 309-333 (2005).
14. Huang, P., Chandra, V. & Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 72, 247-272 (2010).
15. Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
16. Darimont, B. D. et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12, 3343-3356 (1998).
17. Renaud, J. P. et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689 (1995).
18. Chandra, V. et al. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 456, 350-356 (2008).
19. Xu, H. E. et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415, 813-817 (2002).
20. Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997).
21. Nettles, K. W. et al. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol. Cell 13, 317-327 (2004).
22. Shiau, A. K. et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9, 359-364 (2002).
23. Bruning, J. B. et al. Coupling of receptor conformation and ligand orientation determine graded activity. Nat. Chem. Biol. 6, 837-843 (2010).
24. Nettles, K. W. et al. NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat. Chem. Biol. 4, 241-247 (2008).
25. Hughes, T. S. et al. Ligand and receptor dynamics contribute to the mechanism of graded PPARg agonism. Structure 20, 139-150 (2012).
26. Bruning, J. B. et al. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15, 1258-1271 (2007).
27. Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-481 (2011).
28. Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187-192 (2002).
29. Pogenberg, V. et al. Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J. Biol. Chem. 280, 1625-1633 (2005).
30. Schulman, I. G., Li, C., Schwabe, J. W. & Evans, R. M. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev. 11, 299-308 (1997).
31. Willy, P. J. & Mangelsdorf, D. J. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev. 11, 289-298 (1997).
32. Westin, S. et al. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395, 199-202 (1998).
33. DiRenzo, J. et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol. Cell. Biol. 17, 2166-2176 (1997).
34. Forman, B. M., Umesono, K., Chen, J. & Evans, R. M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81, 541-550 (1995).
35. Castillo, A. I. et al. A permissive retinoid X receptor/thyroid hormone receptor heterodimer allows stimulation of prolactin gene transcription by thyroid hormone and 9cRA. Mol. Cell. Biol. 24, 502-513 (2004).
36. Li, D., Li, T., Wang, F., Tian, H. & Samuels, H. H. Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. Mol. Cell. Biol. 22, 5782-5792 (2002).
37. Lu, J., Cistola, D. P. & Li, E. Analysis of ligand binding and protein dynamics of human retinoid X receptor alpha ligand-binding domain by nuclear magnetic resonance. Biochemistry 45, 1629-1639 (2006).
38. Nagy, L. & Schwabe, J. W. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29, 317-324 (2004).
39. Kojetin, D. & Burris, T. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Mol. Pharmacol. 83, 1-8 (2012).
40. Yan, X., Broderick, D., Leid, M. E., Schimerlik, M. I. & Deinzer, M. L. Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. Biochemistry 43, 909-917 (2004).
41. Yan, X. et al. Investigation of ligand interactions with human RXRalpha by hydrogen/deuterium exchange and mass spectrometry. J. Am. Soc. Mass Spectrom. 17, 1510-1517 (2006).
42. Yan, X. et al. Deuterium exchange and mass spectrometry reveal the interaction differences of two synthetic modulators of RXRalpha LBD. Protein Sci. 16, 2491-2501 (2007).
43. Singarapu, K. K. et al. Ligand-specific structural changes in the vitamin D receptor in solution. Biochemistry 50, 11025-11033 (2011).
44. Zhang, J. et al. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure 18, 1332-1341 (2010).
45. Wright, E. et al. Helix 11 dynamics is critical for constitutive androstane receptor activity. Structure 19, 37-44 (2011).
46. Egea, P. F., Mitschler, A. & Moras, D. Molecular recognition of agonist ligands by RXRs. Mol. Endocrinol. 16, 987-997 (2002).
47. Svensson, S. et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 22, 4625-4633 (2003).
48. Gampe, Jr. R. T. et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5, 545-555 (2000).
49. Chalmers, M. J. et al. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal. Chem. 78, 1005-1014 (2006).
50. Gampe, Jr. R. T. et al. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev. 14, 2229-2241 (2000).
51. Lu, J., Chen, M., Stanley, S. E. & Li, E. Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution. Biochem. Biophys. Res. Commun. 365, 42-46 (2008).
52. Wiebel, F. F. & Gustafsson, J. A. Heterodimeric interaction between retinoid X receptor alpha and orphan nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of nuclear receptor activation. Mol. Cell. Biol. 17, 3977-3986 (1997).
53. Li, D., Yamada, T., Wang, F., Vulin, A. I. & Samuels, H. H. Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer. J. Biol. Chem. 279, 7427-7437 (2004).
54. Perez, E., Bourguet, W., Gronemeyer, H. & de Lera, A. R. Modulation of RXR function through ligand design. Biochim. Biophys. Acta 1821, 57-69 (2012).
55. Venalainen, T., Molnar, F., Oostenbrink, C., Carlberg, C. & Perakyla, M. Molecular mechanism of allosteric communication in the human PPARalpha-RXRalpha heterodimer. Proteins 78, 873-887 (2010).
56. Hughes, T. S. et al. An alternate binding site for PPARg ligands. Nat Commun 5, 3571 (2014).
57. Acton, 3rd J. J. et al. Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 15, 357-362 (2005).
58. Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293 (1995).
59. Johnson, B. A. Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol. Biol. 278, 313-352 (2004).
60. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
61. Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948-1954 (2002).
62. Strong, M. et al. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 8060-8065 (2006).
63. Brunger, A. T., DeLaBarre, B., Davies, J. M. & Weis, W. I. X-ray structure determination at low resolution. Acta Crystallogr. D Biol. Crystallogr. 65, 128-133 (2009).
64. DeLaBarre, B. & Brunger, A. T. Considerations for the refinement of lowresolution crystal structures. Acta Crystallogr. D Biol. Crystallogr. 62, 923-932 (2006).
65. Painter, J. & Merritt, E. A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450 (2006).
66. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
67. McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr. D Biol. Crystallogr. 67, 386-394 (2011).
68. Chalmers, M. J. et al. Methods for the analysis of high precision differential hydrogen deuterium exchange data. Int. J. Mass Spectrom. 302, 59-68 (2011).
69. Pascal, B. D. et al. HDX workbench: software for the analysis of H/D exchange MS data. J. Am. Soc. Mass Spectrom. 23, 1512-1521 (2012).
70. Pascal, B. D., Chalmers, M. J., Busby, S. A. & Griffin, P. R. HD desktop: an integrated platform for the analysis and visualization of H/D exchange data. J. Am. Soc. Mass Spectrom. 20, 601-610 (2009).